V-Wave is a technology company.
V-Wave has raised $196.0M across 3 funding rounds.
V-Wave has raised $196.0M in total across 3 funding rounds.
V-Wave has raised $196.0M in total across 3 funding rounds.
V-Wave's investors include Deerfield Management.
# V-Wave: Medical Device Company Overview
V-Wave is a medical device company focused on developing innovative cardiovascular implants for patients with heart failure. Founded in Israel in 2009, the company specializes in minimally invasive percutaneous technologies that address a significant treatment gap in heart failure care.[1] V-Wave was acquired by Johnson & Johnson in October 2024 and now operates as part of Johnson & Johnson MedTech.[1][3]
The company's flagship product, the Ventura Interatrial Shunt, is designed to treat heart failure with reduced ejection fraction (HFrEF) by creating a shunt between the left and right atrium to reduce elevated left atrial pressure.[4] This device targets approximately 800,000 patients annually in the U.S. who experience HFrEF, representing a substantial market opportunity.[5] The Ventura has received FDA Breakthrough Device Designation and CE Marking, positioning it as a potentially first-to-market solution in its category.[1][4]
V-Wave was established in 2009 in Israel with a mission to develop percutaneous implantable technologies for chronic heart failure patients.[1] The company was built on a foundation of science, engineering, and medicine, drawing on decades of expertise in these fields.[4]
The company gained significant momentum through regulatory recognition: it received FDA Breakthrough Device Designation for heart failure in August 2019 and a second breakthrough designation for pulmonary arterial hypertension in September 2019, followed by CE Marking in 2020.[5] Johnson & Johnson began investing in V-Wave in 2016, eventually leading to the company's acquisition announcement in August 2024 for an upfront payment of $600 million, with potential milestone payments up to $1.1 billion.[3][5] The acquisition closed on October 9, 2024.[3]
V-Wave operates within the structural interventional cardiology sector, addressing a growing clinical need as heart failure prevalence increases globally. The company's acquisition by Johnson & Johnson reflects broader industry trends: major healthcare conglomerates are consolidating innovative medical device startups to expand their cardiovascular portfolios and reach specialized cardiologist networks.[3]
The timing of V-Wave's acquisition is significant because it demonstrates J&J's strategic commitment to heart failure treatment innovation. The company complements J&J MedTech's existing platforms addressing coronary artery disease, peripheral artery disease, heart recovery, and atrial fibrillation, creating a more comprehensive cardiovascular ecosystem.[3] V-Wave's technology also deepens J&J's relationships with structural interventional cardiologists and heart failure specialists, expanding its influence in a specialized but high-impact medical segment.
V-Wave's integration into Johnson & Johnson MedTech positions the Ventura Interatrial Shunt for accelerated clinical adoption and market penetration. With J&J's manufacturing scale, regulatory expertise, and global distribution network, the device is well-positioned to achieve market leadership in interatrial shunt therapy.[5] The company's focus on an unmet clinical need—treating approximately 800,000 HFrEF patients annually in the U.S. alone—suggests substantial long-term growth potential.
Looking ahead, V-Wave's influence will likely expand as the Ventura moves through final regulatory pathways and enters clinical practice. The device represents a paradigm shift in heart failure management, offering patients a less invasive alternative to traditional surgical interventions. As heart failure prevalence continues to rise globally due to aging populations and chronic disease burden, V-Wave's technology will play an increasingly important role in the cardiovascular treatment landscape.
V-Wave has raised $196.0M across 3 funding rounds. Most recently, it raised $98.0M Series C in December 2021.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Dec 1, 2021 | $98.0M Series C | Deerfield Management | |
| Sep 1, 2020 | $28.0M Series C | Deerfield Management | |
| Apr 1, 2018 | $70.0M Series C | Deerfield Management |